History of Fentanyl: From Medicine to Overdose Crisis

Written and medically reviewed by the clinical team at Ripple Ranch Recovery Center, including licensed therapists, addiction specialists, and medical professionals.

Recovery Starts Here

Whether you’re seeking help for yourself or supporting someone you care about, you don’t have to navigate this alone. Our team is here to guide you with clarity, compassion, and clinically driven care. Connect with us today to explore personalized next steps toward real, sustainable recovery.

Key Takeaways

  • Fentanyl has two parallel histories: a 1960 Belgian lab synthesis for surgical pain control, and an illicit supply that reshaped U.S. overdose risk starting in 2013 1, 4.
  • The third wave hit in 2013 when law-enforcement fentanyl reports jumped 426% in a single year, and counterfeit pills and adulterated stimulants later made the drug supply unreadable by sight 4, 8.
  • The overall age-adjusted overdose death rate fell 26.2% from 2023 to 2024, the largest annual decrease the CDC has recorded in the 2014 to 2024 window, with synthetic-opioid death rates falling 35.6%; even so, fentanyl still appeared in 70% to 80% of overdose deaths and carfentanil detections rose roughly sevenfold 10, 11.
  • Treatment decisions after fentanyl exposure should be individualized: keep naloxone close, consider supervised medical detox, and weigh buprenorphine, methadone, or naltrexone with a clinician who knows the induction risks 13, 15, 16.

Two Fentanyls, One Name: Why the Backstory Matters Right Now

If you are reading this at 2 a.m. because someone you love is using, or because you are early in your own recovery and trying to make sense of what you’ve been up against, start here: the history of fentanyl is really the history of two different drugs that happen to share a name.

One is a prescription medication synthesized in a Belgian lab in 1960 and still used every day in operating rooms, cancer care, and intensive care units 1. The other is illicitly manufactured fentanyl, often shortened to IMF, which began saturating the U.S. drug supply around 2013 and now shows up in heroin, counterfeit pills, cocaine, and methamphetamine 4, 8. Same molecule. Very different stories.

Understanding the split matters because it changes what you do next. The history of fentanyl explains why withdrawal can feel sharper than it did with older opioids, why your clinician may ask careful questions before starting buprenorphine, and why naloxone belongs in a bag near the front door. It also explains the recent, cautious good news in the 2024 data — a story we’ll get to in a few sections.

A Belgian Lab in 1960: How Fentanyl Entered Medicine

Paul Janssen’s Synthesis and the Push for a Faster, Stronger Analgesic

The history of fentanyl begins not on a street corner but at a lab bench in Beerse, Belgium. In 1960, a chemist named Paul Janssen and his team synthesized a new synthetic opioid they hoped would act faster and bind more cleanly to opioid receptors than morphine 1. The goal was practical: surgeons needed a painkiller that could take effect in minutes, wear off predictably, and give anesthesiologists tighter control during operations.

Fentanyl was developed as a potent synthetic opioid with the goal of improving receptor specificity and safety relative to morphine, which meant it could manage severe pain during surgery, childbirth, and intensive care 2. That same potency, the review authors note, also carried real risks the field recognized early, including respiratory depression and muscle rigidity when doses were not carefully controlled 1.

If you are trying to understand why fentanyl exists at all, this is the honest answer. It was built to help people survive serious pain, and it still does that work in hospitals every day. The problem that would reshape American lives decades later was not the molecule itself. It was what happened when a version of that molecule, made outside any pharmacy, started arriving in the drug supply with no label and no dose.

From Operating Rooms to Patches: The Expansion of Pharmaceutical Fentanyl

After its debut as an intravenous anesthetic, fentanyl’s initial U.S. approval dates to 1968, and clinicians later gained a transdermal system — the familiar skin patch — as a way to deliver steady opioid relief to people with chronic cancer pain and other serious conditions 3. That expansion marked the point where fentanyl moved from the operating table into longer-term pain care.

From there, the pharmaceutical track kept branching. Over the following decades, fentanyl became available in transmucosal lozenges, nasal sprays, buccal films, and injectable forms, each designed for a specific clinical situation such as breakthrough cancer pain or procedural sedation 2. These are the versions a hospice nurse, an anesthesiologist, or an ICU team may still use today. They are tightly scheduled, dosed in micrograms, and administered by people trained to watch what the medication is doing to your breathing.

Hold that image in mind, because the history of fentanyl runs on a second track at the same time. While the medical track was adding patches and lozenges, a separate, illicit track was quietly beginning. Clandestinely produced synthetic opioids structurally related to fentanyl were trafficked on the U.S. West Coast in the late 1970s and 1980s, including analogs that had never seen a pharmacy 18. That early illicit episode set the pattern for what would return with far greater force after 2013 5. The rest of this article follows both tracks forward.

The First Illicit Episode: West Coast Analogs in the 1970s and 1980s

Here is a piece of the history of fentanyl that most people miss: the current crisis is not the first time illicit fentanyl showed up in American drug markets. It is the second.

In the late 1970s and through the 1980s, clandestinely produced synthetic opioids structurally related to fentanyl were trafficked on the U.S. West Coast, often appearing on illicit markets in place of or alongside heroin 18. These were analogs, meaning molecules tweaked just enough to differ from pharmaceutical fentanyl while still acting on the same opioid receptors. People buying what they believed was heroin had no way to know what they were actually putting into their bodies.

That first episode did not become the sustained, nationwide crisis the country would later face 18. For a while, the illicit fentanyl problem looked like a contained chapter rather than a trend. It wasn’t. The template, which involved a potent synthetic opioid produced outside any regulated supply chain, pressed into a familiar-looking product, remained available for anyone willing to use it again at scale.

The Third Wave Arrives: 2013-2017 and the Modern Crisis

Why 2013 Became the Turning Point in the History of Fentanyl

If you had to pick a single year when the history of fentanyl changed shape in the United States, 2013 is the one circled on the map. That is when illicitly manufactured fentanyl stopped being a regional West Coast problem and started arriving nationally, mostly as an addition to the heroin supply.

The clearest early signal came from crime labs, not hospitals. Fentanyl identified in U.S. law-enforcement drug submissions jumped 426%, from 1,015 reports in 2013 to 5,343 in 2014 4. In the same window, synthetic-opioid-involved overdose deaths climbed 79%, from 3,105 to 5,544 4. The CDC later folded that moment into its wave framework, naming 2013 the start of the third wave of the opioid epidemic, a wave driven by illicitly manufactured fentanyl and its analogs rather than by prescription painkillers 5.

Why did the curve bend so hard, so fast? The CDC MMWR analysis found that the sharp rise in deaths tracked more closely with fentanyl law-enforcement submissions than with fentanyl prescribing, pointing to the illicit supply as the driver 4. For people buying what they thought was a familiar bag or pill, the dose on any given day became unknowable. That is the real inflection point in the history of fentanyl: not a change in who was using opioids, but a change in what was actually in the supply.

How Analogs and Counterfeit Pills Reshaped Overdose Risk

Once illicit fentanyl had a foothold, the chemistry kept moving. Underground labs began producing fentanyl analogs, which are molecules tweaked slightly from fentanyl itself so they skirt existing drug schedules while still hitting the same opioid receptors. A peer-reviewed review tracking this period documented an unprecedented rise in fentanyl overdose deaths after 2013 and more than a 300% jump in DEA fentanyl encounters from 2014 to 2015 alone 7. Each new analog could be dramatically stronger or weaker than the last, and toxicology labs often struggled to keep up.

The consequence for people using opioids was blunt. During July through December 2016, a CDC field report across ten states found fentanyl in 56.3% of 5,152 opioid overdose deaths, and medical examiners judged fentanyl to be a cause of death in 97.1% of those fentanyl-positive cases 6. By 2016 to 2017, the synthetic-opioid overdose death rate rose another 45.2% in a single year 5.

Two shifts matter most if you are trying to protect yourself or someone you love:

  • First, counterfeit pills pressed to look like oxycodone, hydrocodone, or Xanax started circulating widely, and many contained fentanyl instead of, or in addition to, the advertised ingredient 8.
  • Second, fentanyl showed up as an adulterant in heroin and later in cocaine and methamphetamine, meaning overdose risk was no longer limited to people who thought they were using an opioid at all 8.

The history of fentanyl, from this point forward, is a history of a drug supply you cannot read by looking at it.

The Fourth Wave: Fentanyl, Stimulants, and Xylazine Enter the Mix

By the early 2020s, the history of fentanyl stopped being a story about one drug and became a story about mixtures. Researchers started calling this stretch the fourth wave: illicitly manufactured fentanyl combined with stimulants like methamphetamine and cocaine, and increasingly with a veterinary sedative called xylazine 9. The geography shifted too, with fentanyl-related overdose expanding into western states that had largely been spared during the earlier heroin-driven years 9. For families in Texas, that westward spread is part of why this feels closer to home than it did a decade ago.

The mixing is not accidental. Illicit fentanyl now shows up as an adulterant in heroin, cocaine, methamphetamine, and counterfeit pills pressed to look like prescription medications 8. If you are using a stimulant and have no tolerance to opioids, a hidden fentanyl exposure can stop your breathing before you know what hit you. If you are using opioids and also take something sedating on top, the respiratory risk stacks.

Xylazine adds another layer. A CDC report on adults evaluated for substance-use treatment between July 2022 and September 2023 found that people reporting xylazine use had a median of two previous nonfatal overdoses, compared with one among those who did not report xylazine use, and most xylazine-involved overdose deaths also involved illicitly manufactured fentanyl 12. Xylazine is not an opioid, so naloxone does not reverse its sedating effects, though you still give naloxone because fentanyl is almost always in the picture.

Practically, this changes what a careful assessment looks like. Your clinician should ask about every substance in play, not just opioids, because the history of fentanyl in 2024 is a history of what else is in the bag.

Where Things Stand in 2023 and 2024: A Decline With Warning Signs

Here is where the history of fentanyl finally offers a breath of better news. After nearly a decade of climbing numbers, the national overdose picture started to turn. In 2024, there were 79,384 drug overdose deaths in the United States, and the rate involving synthetic opioids other than methadone — the category that captures fentanyl and its analogs — fell 35.6% from 2023 to 2024, dropping from 22.2 to 14.3 deaths per 100,000 people 11. The overall age-adjusted overdose death rate fell 26.2% in that same period, the largest annual decrease the CDC has recorded in the 2014 to 2024 window 11.

If someone you love is still using, that drop may feel abstract. It is not. It likely reflects a mix of wider naloxone distribution, more people reaching treatment, changing drug composition, and shifts in the illicit supply itself 10. Fewer families are getting the call this year than last. That matters.

The warning signs sit right next to the good news. Illicitly manufactured fentanyl was still estimated to be involved in roughly 72,000 overdose deaths in 2023, and it remained present in approximately 70% to 80% of overdose deaths across most U.S. regions through the recent surveillance period, though the CDC describes 2024 data as preliminary and subject to jurisdictional variation 10. The supply is also getting stranger. Carfentanil, a fentanyl analog, showed a roughly sevenfold rise in overdose detections, from 29 deaths during January through June 2023 to 238 during the same months in 2024 10.

What This History Changes About Treatment Today

Naloxone, Nalmefene, and Overdose Reversal in the Fentanyl Era

One of the most common questions people ask after reading the history of fentanyl is whether the overdose-reversal tools they grew up hearing about still work. The short answer: yes. SAMHSA identifies naloxone and nalmefene as the FDA-approved opioid-overdose reversal medications, and both can reverse an overdose involving fentanyl 15. NIDA notes that standard-strength naloxone still works to reverse most fentanyl overdoses, though emergency services should be called immediately 16.

What changes in the fentanyl era is the practical margin. Fentanyl acts fast and depresses breathing quickly, so the person responding has less time to notice and act. That is why keeping naloxone within reach — a nightstand, a kitchen drawer, a bag by the door — matters more now than it did a decade ago.

Reversal is not treatment. SAMHSA is clear that medical intervention remains critical after a reversal dose is given, because the opioid may outlast the antidote and breathing can slow again 15. If an overdose happens, give the dose, call 911, and stay until help arrives.

Medical Detox and the Case for Supervised Withdrawal

If you or your loved one has been using fentanyl, the first clinical conversation is usually about withdrawal. The history of fentanyl matters here because fentanyl’s pharmacology — its potency and the way it lingers in body tissue — can make early withdrawal feel more intense and less predictable than withdrawal from older opioids 2. That is not a character problem. It is chemistry.

Medical detox is supervised withdrawal in a setting where clinicians can monitor your breathing, hydration, blood pressure, and symptoms around the clock, and adjust medications as the picture changes. For fentanyl specifically, that supervision gives the care team room to time the next medication decision carefully, especially if buprenorphine is on the table. We’ll get to that choice in a moment.

Buprenorphine, Methadone, and Naltrexone: Choosing a Medication After Fentanyl Exposure

Medications for opioid use disorder, often shortened to MOUD, are the backbone of long-term treatment. NIDA lists three: methadone, buprenorphine, and naltrexone 16. Each works differently, and the history of fentanyl has changed how clinicians think about matching the medication to the person.

Buprenorphine is a partial opioid agonist that eases cravings and withdrawal while blocking other opioids from fully activating the same receptors. The complication is something called precipitated withdrawal — a sudden, severe worsening of withdrawal when buprenorphine is taken while another opioid is still active in the body. A study of 1,679 people seeking treatment across 49 U.S. addiction-treatment centers found significantly higher odds of severe withdrawal when buprenorphine was taken within 24 hours, or within 24 to 48 hours, after fentanyl use 13. A separate emergency-department cohort told a quieter story: among patients who reported fentanyl use before coming in, only 3 people, or 2.6%, experienced precipitated withdrawal after buprenorphine initiation 14. Both findings are real. Together, they argue for individualized induction by clinicians who know what they are watching for, not a one-size approach.

Methadone is a full agonist taken daily, typically through a licensed program. A NIDA commentary described a 2020 naturalistic follow-up in which 53% of patients who tested positive for fentanyl at methadone-treatment intake remained in treatment after one year, compared with 47% who tested negative, and nearly all retained patients achieved remission in that study 17. For some people exposed to fentanyl, especially those who have struggled with buprenorphine induction or treatment retention, methadone deserves a serious conversation.

Naltrexone, the third option, blocks opioid effects entirely and requires a period of complete opioid abstinence before starting 16. It fits a specific moment in recovery rather than the earliest days after fentanyl exposure. The right medication is the one chosen with you, by a clinician who has your full picture — not the one someone recommends based on headlines about the history of fentanyl.

Finding Care in the Texas Hill Country, San Antonio, and Austin

If the history of fentanyl has brought you to this page, the next step is smaller than it feels. You do not have to understand every wave of the crisis to make one phone call or send one message. You just have to start a conversation with someone who can help you figure out what kind of care fits.

For people in San Antonio, Austin, and the Texas Hill Country, that conversation usually begins with a few practical questions:

  • What has been used, and when was the last use?
  • Is anything else in the mix, including stimulants, benzodiazepines, alcohol, or xylazine 12?
  • Is medical detox the right first step, or is a direct admission to residential care safer?
  • Would methadone, buprenorphine, or naltrexone fit the picture better, and how will the team handle induction given what we know about fentanyl exposure 13, 14, 16?

You do not need to answer any of this on your own. A qualified clinician can walk you through assessment, verify your benefits, and talk honestly about what residential treatment and step-down outpatient support could look like for you or your loved one. If it is late and you are reading this for someone else, a live chat or short form counts as a real first step. The history of fentanyl is heavy. Your next move does not have to be.

Talk With Someone About Fentanyl Treatment

Call to discuss your concerns and explore a treatment next step for you or someone you love.

Frequently Asked Questions

When was fentanyl invented and why was it created?

Fentanyl was synthesized in 1960 by chemist Paul Janssen and his team at a laboratory in Beerse, Belgium 1. The goal was practical: develop a synthetic opioid that worked faster and bound more selectively to opioid receptors than morphine, giving anesthesiologists tighter control during surgery 2. The history of fentanyl starts there, as a medical breakthrough designed to manage serious pain, not as a street drug.

What is the difference between pharmaceutical fentanyl and illicitly manufactured fentanyl?

Pharmaceutical fentanyl is a regulated prescription medication available in patches, lozenges, nasal sprays, and injectable forms, dosed in micrograms by trained clinicians 2, 3. Illicitly manufactured fentanyl, often called IMF, is produced outside any regulated supply chain and shows up in heroin, counterfeit pills, cocaine, and methamphetamine with no reliable dose 8. The history of fentanyl runs on both tracks at once, and the illicit version drives today’s overdose risk.

When did fentanyl become the main driver of the U.S. overdose crisis?

The CDC identifies 2013 as the start of the third wave of the opioid epidemic, driven by illicitly manufactured fentanyl and its analogs rather than prescription painkillers 5. By July through December 2016, fentanyl was already detected in 56.3% of 5,152 opioid overdose deaths across ten states studied 6. That is the stretch when the history of fentanyl shifted from a mostly medical story to a public-health emergency.

Does naloxone still work on a fentanyl overdose?

Yes. SAMHSA identifies naloxone and nalmefene as FDA-approved opioid-overdose reversal medications, and NIDA confirms standard-strength naloxone still reverses most fentanyl overdoses 15, 16. What changes is timing. Fentanyl works fast, so give the dose, call 911, and stay with the person until help arrives. SAMHSA is clear that medical care after a reversal is critical, because the opioid can outlast the antidote and breathing can slow again 15.

Why is starting buprenorphine harder after fentanyl use?

Fentanyl lingers in body tissue longer than older opioids, which can trigger precipitated withdrawal if buprenorphine is started too soon. A study of 1,679 people across 49 U.S. treatment centers found significantly higher odds of severe withdrawal when buprenorphine was taken within 24 to 48 hours of fentanyl use 13. A smaller emergency-department cohort reported precipitated withdrawal in just 2.6% of patients 14. Induction should be individualized by a clinician.

Are overdose deaths from fentanyl actually declining?

Yes, with caveats. The CDC reports 79,384 drug overdose deaths in 2024, and the synthetic-opioid death rate fell 35.6% from 2023 to 2024 11. That is real progress worth naming. The warning signs still matter, though: illicitly manufactured fentanyl was present in about 70% to 80% of overdose deaths in most regions, and carfentanil detections rose roughly sevenfold between early 2023 and early 2024, though the CDC describes 2024 data as preliminary and subject to jurisdictional variation 10. The history of fentanyl keeps moving.

References

  1. The history and development of the fentanyl series. https://pubmed.ncbi.nlm.nih.gov/1517629/
  2. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. https://pmc.ncbi.nlm.nih.gov/articles/PMC7233332/
  3. Fentanyl (fen’ ta nil) Transdermal System, CII. https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=242759ef-cb6d-4e3e-9f8d-5e31efa1f289
  4. Fentanyl Law Enforcement Submissions and Increases in Synthetic Opioid-Involved Overdose Deaths — 27 States, 2013–2014. https://www.cdc.gov/mmwr/volumes/65/wr/mm6533a2.htm
  5. Drug and Opioid-Involved Overdose Deaths — United States, 2013–2017. https://www.cdc.gov/mmwr/volumes/67/wr/mm675152e1.htm
  6. Deaths Involving Fentanyl, Fentanyl Analogs, and U-47700 — 10 States, July–December 2016. https://www.cdc.gov/mmwr/volumes/66/wr/mm6643e1.htm
  7. The Fentanyl Epidemic and Evolution of Fentanyl Analogs in the United States and the European Union. https://pubmed.ncbi.nlm.nih.gov/30305277/
  8. The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies. https://pubmed.ncbi.nlm.nih.gov/31712552/
  9. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. https://pubmed.ncbi.nlm.nih.gov/33965972/
  10. Detection of Illegally Manufactured Fentanyls and Carfentanil in Drug Overdose Deaths — United States, 2021–2024. https://www.cdc.gov/mmwr/volumes/73/wr/mm7348a2.htm
  11. Drug Overdose Deaths in the United States, 2023–2024. https://www.cdc.gov/nchs/products/databriefs/db549.htm
  12. Reported Xylazine Use Among Adults Aged ≥18 Years Evaluated for Substance Use Treatment — United States, July 2022–September 2023. https://www.cdc.gov/mmwr/volumes/73/wr/mm7326a2.htm
  13. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl. https://pubmed.ncbi.nlm.nih.gov/34816821/
  14. Buprenorphine initiation and rates of associated precipitated withdrawal in patients with fentanyl use in an urban emergency department. https://pubmed.ncbi.nlm.nih.gov/39626454/
  15. Opioid Overdose Reversal Medications (OORM). https://www.samhsa.gov/substance-use/treatment/overdose-prevention/opioid-overdose-reversal
  16. Fentanyl. https://nida.nih.gov/research-topics/fentanyl
  17. To address the fentanyl crisis, greater access to methadone is needed. https://nida.nih.gov/about-nida/noras-blog/2024/07/to-address-the-fentanyl-crisis-greater-access-to-methadone-is-needed
  18. Drugs of Abuse: A DEA Resource Guide, 2024 Edition. https://www.dea.gov/sites/default/files/2025-01/Synthetic-Opioids-Drug-Fact-Sheet.pdf

Guidance for You or Someone You Care About

Every recovery journey starts with a conversation—whether you’re reaching out for yourself, a loved one, or a client in need of care. At Ripple Ranch, we meet you where you are with thoughtful guidance and individualized treatment planning. Let’s take the next step forward, together.

Table of Contents

Learn More About Ripple Ranch Recovery Center

Our team is standing by to discuss your situation and options. Your call is fully confidential, and no obligation is required